|
1
|
Chen Z, He M, Chen J, Li C and Zhang Q:
Long non-coding RNA SNHG7 inhibits NLRP3-dependent pyroptosis by
targeting the miR-34a/SIRT1 axis in liver cancer. Oncol Lett.
20:893–901. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Parkin DM and Steliarova-Foucher
E: Estimates of cancer incidence and mortality in Europe in 2008.
Eur J Cancer. 46:765–781. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xu J and Xu Y: The lncRNA MEG3
downregulation leads to osteoarthritis progression via miR-16/SMAD7
axis. Cell Biosci. 7:692017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu J, Tang T, Wang GD and Liu B:
lncRNA-H19 promotes hepatic lipogenesis by directly regulating
miR-130a/PPARgamma axis in non-alcoholic fatty liver disease.
Biosci Rep. 39:BSR201817222019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang CA, Li JP, Yen JC, Lai IL, Ho YC,
Chen YC, Lan JL and Chang JG: lncRNA NTT/PBOV1 axis promotes
monocyte differentiation and is elevated in rheumatoid arthritis.
Int J Mol Sci. 19:28062018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Harries LW: Long non-coding RNAs and human
disease. Biochem Soc Trans. 40:902–906. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jiang MC, Ni JJ, Cui WY, Wang BY and Zhuo
W: Emerging roles of lncRNA in cancer and therapeutic
opportunities. Am J Cancer Res. 9:1354–1366. 2019.PubMed/NCBI
|
|
9
|
Wang Z, Huang D, Huang J, Nie K, Li X and
Yang X: lncRNA TMPO-AS1 exerts oncogenic roles in HCC through
regulating miR-320a/SERBP1 Axis. Onco Targets Ther. 13:6539–6551.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Teng F, Zhang JX, Chang QM, Wu XB, Tang
WG, Wang JF, Feng JF, Zhang ZP and Hu ZQ: lncRNA MYLK-AS1
facilitates tumor progression and angiogenesis by targeting
miR-424-5p/E2F7 axis and activating VEGFR-2 signaling pathway in
hepatocellular carcinoma. J Exp Clin Cancer Res. 39:2352020.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu X, Peng D, Cao Y, Zhu Y, Yin J, Zhang
G, Peng X and Meng Y: Upregulated lncRNA DLX6-AS1 underpins
hepatocellular carcinoma progression via the miR-513c/Cul4A/ANXA10
axis. Cancer Gene Ther. 28:486–501. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wei F, Yang L, Jiang D, Pan M, Tang G,
Huang M and Zhang J: Long noncoding RNA DUXAP8 contributes to the
progression of hepatocellular carcinoma via regulating
miR-422a/PDK2 axis. Cancer Med. 9:2480–2490. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Komoll RM, Hu Q, Olarewaju O, von Döhlen
L, Yuan Q, Xie Y, Tsay HC, Daon J, Qin R, Manns MP, et al:
MicroRNA-342-3p is a potent tumour suppressor in hepatocellular
carcinoma. J Hepatol. 74:122–134. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang Y, Pan Q and Shao Z:
Tumor-Suppressive role of microRNA-202-3p in hepatocellular
carcinoma through the KDM3A/HOXA1/MEIS3 pathway. Front Cell Dev
Biol. 8:5560042021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao L, Han T, Li Y, Sun J, Zhang S, Liu
Y, Shan B, Zheng D and Shi J: The lncRNA SNHG5/miR-32 axis
regulates gastric cancer cell proliferation and migration by
targeting KLF4. FASEB J. 31:893–903. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang Y, Wang J, An W, Chen C, Wang W, Zhu
C, Chen F, Chen H, Zheng W and Gong J: MiR-32 inhibits
proliferation and metastasis by targeting EZH2 in glioma. Technol
Cancer Res Treat. 18:15330338198541322019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu YJ, Zhou HG, Chen LH, Qu DC, Wang CJ,
Xia ZY and Zheng JH: MiR-32-5p regulates the proliferation and
metastasis of cervical cancer cells by targeting HOXB8. Eur Rev Med
Pharmacol Sci. 23:87–95. 2019.PubMed/NCBI
|
|
18
|
Carnero A, Blanco-Aparicio C, Renner O,
Link W and Leal JF: The PTEN/PI3K/AKT signalling pathway in cancer,
therapeutic implications. Curr Cancer Drug Targets. 8:187–198.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chalhoub N and Baker SJ: PTEN and the
PI3-kinase pathway in cancer. Annu Rev Pathol. 4:127–150. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yan SY, Chen MM, Li GM, Wang YQ and Fan
JG: MiR-32 induces cell proliferation, migration, and invasion in
hepatocellular carcinoma by targeting PTEN. Tumour Biol.
36:4747–4755. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang Y, Zhu Z, Huang S, Zhao Q, Huang C,
Tang Y, Sun C, Zhang Z, Wang L, Chen H, et al: lncRNA XIST
regulates proliferation and migration of hepatocellular carcinoma
cells by acting as miR-497-5p molecular sponge and targeting PDCD4.
Cancer Cell Int. 19:1982019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu L, Yue H, Liu Q, Yuan J, Li J, Wei G,
Chen X, Lu Y, Guo M, Luo J and Chen R: lncRNA MT1JP functions as a
tumor suppressor by interacting with TIAR to modulate the p53
pathway. Oncotarget. 7:15787–15800. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu Y, Zhang G, Zou C, Zhang H, Gong Z,
Wang W, Ma G, Jiang P and Zhang W: lncRNA MT1JP suppresses gastric
cancer cell proliferation and migration through
MT1JP/miR-214-3p/RUNX3 axis. Cell Physiol Biochem. 46:2445–2459.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen J, Lou J, Yang S, Lou J, Liao W, Zhou
R, Qiu C and Ding G: MT1JP inhibits glioma progression via negative
regulation of miR-24. Oncol Lett. 19:334–342. 2020.PubMed/NCBI
|
|
26
|
Yu H, Wang S, Zhu H and Rao D: lncRNA
MT1JP functions as a tumor suppressor via regulating miR-214-3p
expression in bladder cancer. J Cell Physiol. Feb 20–2019.(Epub
ahead of print). doi: 10.1002/jcp.28274. View Article : Google Scholar
|
|
27
|
Wu JH, Xu K, Liu JH, Du LL, Li XS, Su YM
and Liu JC: lncRNA MT1JP inhibits the malignant progression of
hepatocellular carcinoma through regulating AKT. Eur Rev Med
Pharmacol Sci. 24:6647–6656. 2020.PubMed/NCBI
|
|
28
|
Chen CY, Chen J, He L and Stiles BL: PTEN:
Tumor suppressor and metabolic regulator. Front Endocrinol
(Lausanne). 9:3382018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gao X, Qin T, Mao J, Zhang J, Fan S, Lu Y,
Sun Z, Zhang Q, Song B and Li L: PTENP1/miR-20a/PTEN axis
contributes to breast cancer progression by regulating PTEN via
PI3K/AKT pathway. J Exp Clin Cancer Res. 38:2562019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang YN, Xu F, Zhang P, Wang P, Wei YN, Wu
C and Cheng SJ: MicroRNA-575 regulates development of gastric
cancer by targeting PTEN. Biomed Pharmacother. 113:1087162019.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gao ZQ, Wang JF, Chen DH, Ma XS, Wu Y,
Tang Z and Dang XW: Long non-coding RNA GAS5 suppresses pancreatic
cancer metastasis through modulating miR-32-5p/PTEN axis. Cell
Biosci. 7:662017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stambolic V, MacPherson D, Sas D, Lin Y,
Snow B, Jang Y, Benchimol S and Mak TW: Regulation of PTEN
transcription by p53. Mol Cell. 8:317–325. 2001. View Article : Google Scholar : PubMed/NCBI
|
